LivaNova PLC (LIVN) FinancialsLIVNLivaNova PLC

LivaNova PLC (LIVN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cardiopulmonary, accounting for 56.7% of total sales, equivalent to $221.58M. Other significant revenue streams include Neuromodulation and Other. Understanding this composition is critical for investors evaluating how LIVN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, LivaNova PLC maintains a gross margin of 70.07%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.08%, while the net margin is 3.37%. These profitability ratios, combined with a Return on Equity (ROE) of 7.61%, provide a clear picture of how effectively LIVN converts its operational activities into shareholder value.

In the context of the broader market, LIVN competes directly with industry leaders such as ICUI and NVST. With a market capitalization of $4.53B, it holds a significant position in the sector. When comparing efficiency, LIVN's gross margin of 70.07% stands against ICUI's 42.61% and NVST's 56.71%. Such benchmarking helps identify whether LivaNova PLC is trading at a premium or discount relative to its financial performance.

LivaNova reported a gross margin of 70.07% in Q2 2026, reflecting strong profitability. The company also achieved an EPS of $1.02, exceeding estimates, and has raised its revenue growth forecast to 8%-9% for 2026, indicating solid growth prospects.